About Cellusion
Cellusion is a company based in Minato (Japan) founded in 2015. Cellusion has raised $29.71 million across 2 funding rounds from investors including Nikon, Sparx Group and TOHO HOLDINGS. Cellusion operates in a competitive market with competitors including CorneaGen, EyeGate, Avedro, CorNeat Vision and EyeYon, among others.
- Headquarter Minato, Japan
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website cellusion.jp
- Total Equity Funding$29.71M (USD)
in 2 rounds
- Latest Funding Round$20.22M (USD), Series C
Jun 2023
- InvestorsNikon
& 12 more
Funding Insights of Cellusion
Cellusion has successfully raised a total of $29.71M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $20.22 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.71M
- Total Rounds 2
- Last Round Series C — $20.22M
- First Round $9.49M
(Jan 2022)
- Investors Count 13
All 2 funding rounds of Cellusion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $20.22M | Series C | – | JIC Venture Growth Investments, Nissay Capital | |
| Jan 2022 | $9.49M | Series B | – | DBJ Capital, Keio Innovation Initiative | – |
13 investors in total: 13 institutional.
Investors in Cellusion
Cellusion has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Nikon, Sparx Group and TOHO HOLDINGS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on growth stage companies | – | j-vgi.co.jp | Minato City, Japan | |
Venture capital firm investing in biotech, adtech sectors | – | nissay-cap.co.jp | Chiyoda City, Japan | |
Early-stage investments are targeted by Axil Capital, a VC firm. | – | axilcapital.com | Minato City, Japan | |
Seed and Early stage VC firm investing in Japan | – | ut-ec.co.jp | Tokyo, Japan | |
Venture capital investments are provided to innovative startups by DBJ Capital. | – | dbj-cap.jp | Japan | |
- | – | smbc-vc.co.jp | - | |
Stage-agnostic investments in Japanese tech and life sciences are made. | 2015 | keio-innovation.co.jp | Tokyo, Japan | |
Asset management, accounting, and real estate brokerage services are provided. | 1989 | sparxgroup.com | Minato City, Japan | |
Nikon is recognized as a key technology solutions company. | 1917 | nikon.com | Minato, Japan | |
- | – | aiscapgroup.com | - |
Investor details for Cellusion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellusion
1 people are tracked at Cellusion (1 in leadership).
| Name | Role | Group |
|---|---|---|
Shin Hatou | CEO | Leadership |
Complete people profiles for Cellusion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellusion
3 dated milestones of Cellusion across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Cellusion is founded.
- Funding First funding round of $9.5M.
- Funding Latest funding round, Series C, of $20.2M.
Competitors of Cellusion
Cellusion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, EyeGate, Avedro, CorNeat Vision and EyeYon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases | |
| biolatticetech.com | 2017 | Philadelphia, United States | – | – | Solutions for tissue repair and restoration are developed. |
Detailed competitors of Cellusion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellusion
The website of Cellusion (cellusion.jp) receives about 4.7K visits a month and ranks #4,154,580 among all websites worldwide, #5,162 in Biotechnology and Pharmaceuticals.
- Monthly visits4.7K
▲ 23.2% vs previous month
- Unique visitors1.5K
per month
- Global rank#4,154,580
among all websites
- Category rank#5,162
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.3
- Average visit1 min 05 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Cellusion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
tdc-eye.com | tdc-eye.com | 100% | – | #4,459,707 | – |
shimazaki-eye.com | shimazaki-eye.com | 98% | – | #5,480,999 | – |
tdc.ac.jp | tdc.ac.jp | 72% | – | – | – |
ks-frozen.co.jp | ks-frozen.co.jp | 38% | – | #2,981,257 | – |
Latest news on Cellusion
Complete news archive for Cellusion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cellusion
10 companies that operate in the same segment as Cellusion (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellusion
Cellusion was founded in 2015 and raised its 1st funding round 7 years after it was founded.
Cellusion is headquartered in Minato, Japan. It is registered at Minato, Tokyo, Japan.
Shin Hatou is the current CEO of Cellusion.
Cellusion is a funded company, having raised a total of $29.71M across 2 funding rounds to date. The company's 1st funding round was a Series B of $9.49M, raised on Jan 2022.
Cellusion was founded in 2015 and is based in Minato City, Japan. Operations are centered in the biotechnology sector, with a focus on regenerative medicine. iPS cell-derived materials are developed for transplantation to replace damaged corneal endothelium. This approach is applied to treat bullous keratopathy through direct injection into the cornea, supporting clinical advancements in ocular therapies.
Cellusion has 13 investors. Key investors include Nikon, Sparx Group, TOHO HOLDINGS, Keio Innovation Initiative, and Toyo Seikan Kaisha.